Ockerman, Kyle

In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer

Dubrot, J., Du, P. P., Lane-Reticker, S. K., Kessler, E. A., Muscato, A. J., Mehta, A., Freeman, S. S., Allen, P. M., Olander, K. E., Ockerman, K. M., et al. (2022) · Nature Immunology

Cancer Immunotherapy and BiomarkersImmune Cell Function and Interaction

Cited by 218

Public interest in the off-label use of glucagon-like peptide 1 agonists (Ozempic) for cosmetic weight loss: a Google trends analysis.

Han, S. H., Safeek, R., Ockerman, K., Trieu, N., Mars, P., Klenke, A., Furnas, H., & Sorice-Virk, S. (2023) · Aesthetic Surgery Journal

Pharmacology and Obesity TreatmentData-Driven Disease Surveillance

Cited by 210

Practice Patterns and Perspectives of the Off-Label Use of GLP-1 Agonists for Cosmetic Weight Loss

Han, S. H., Ockerman, K., Furnas, H., Mars, P., Klenke, A., Ching, J., Momeni, A., & Sorice-Virk, S. (2024) · Aesthetic Surgery Journal

Pharmacology and Obesity TreatmentBody Contouring and Surgery

Cited by 40